Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States

Farrukh Awan, Nadine Zawadzki, Anna Teschemaker, Kathy Wojtas, David Satre, Vikram Shetty, Dipen Patel, Fady Fam, Ryan Crowley, Jason Shafrin

Blood (2025) 146 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2025-2627

Published: 2025

Journal Articles

Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation

Julio Alvarenga Thiebaud, Alejandro Marinos Velarde, Stephen Chung, Clayton Jackson, Robert Collins, Vivian Irizarry Gatell, Yazan Madanat, Aimaz Afrough, Farrukh Awan, Praveen Ramakrishnan Geethakumari, Elif Yilmaz, Heather Wolfe, Larry Anderson, Adeel Khan, Yossel Alvarenga, Sanil Sansar, Chantalle Lacelle

Blood (2025) 146 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2025-4307

Published: 2025

Journal Articles

Acalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: A ‘real-world’ study of efficacy and safety at a tertiary academic medical center

Ken Zou, Truman Koh, Heather Wolfe, Farrukh Awan

Blood (2025) 146 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2025-4558

Published: 2025

Journal Articles

Policy and systems solutions to expand timely access to CAR T-cell therapy: Findings from a national survey of oncology professionals

Caroline Offit, Nakhle Saba, Peter Riedell, Arnela Kajdic Tarantino, Nicole Colwell, Kimberly Demirhan, Molly Kisiel, Farrukh Awan

Blood (2025) 146 (Supplement 1): 2638.

https://doi.org/10.1182/blood-2025-2638

Published: 2025

Journal Articles

T-cell tolerant fraction as a predictor of graft-versus-host disease in murine and human allogeneic hematopoietic cell transplantation

Jared Ostmeyer, Andrew Cox, Amir Toor, Farrukh Awan

Blood (2025) 146 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2025-4248

Published: 2025

Journal Articles

Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study

Mary-Margaret Keating, Tae Min Kim, Farrukh Awan, Jingxian Cai, Amulya Uppala, Aafia Chaudhry, Hesham Mohamed, Manjusha Namuduri, Jan Walewski

Blood (2025) 146 (Supplement 1): 5523.

https://doi.org/10.1182/blood-2025-5523

Published: 2025

Journal Articles

Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies

Ashwin Sunderraj, Truman Koh, Rudy Mrad, Farrukh Awan

Blood (2025) 146 (Supplement 1): 8078.

https://doi.org/10.1182/blood-2025-8078

Published: 2025

Journal Articles

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison

Blood (2022) 140 (20): 2142–2145.

https://doi.org/10.1182/blood.2022016953

Published: 2022

Includes: Supplemental data

Journal Articles

Hypertension and incident cardiovascular events following ibrutinib initiation

Tyler Dickerson, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Kyle Porter, Devin Haddad, Avirup Guha, Kerry A. Rogers, Seema Bhat, John C. Byrd, Jennifer A. Woyach, Farrukh Awan, Daniel Addison

Blood (2019) 134 (22): 1919–1928.

https://doi.org/10.1182/blood.2019000840

Published: 2019

Includes: Supplemental data

Journal Articles

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh Awan, MD MS, Jeffrey A. Jones, MD MPH, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2953.

https://doi.org/10.1182/blood.V126.23.2953.2953

Published: 2015

Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2015) 126 (23): 318.

https://doi.org/10.1182/blood.V126.23.318.318

Published: 2015

Journal Articles

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle Beckwith, Yuh-Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh Awan, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Jessica MacMurray, Santosh B. Salunke, Ching-Shih Chen, Mitch A. Phelps, John C. Byrd, Amy J. Johnson

Blood (2015) 125 (2): 284–295.

https://doi.org/10.1182/blood-2014-06-583518

Published: 2015

Includes: Supplemental data

Journal Articles

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Jason Gotlib, MD MS, Hanneke C. Kluin-Nelemans, MD PhD, Tracy I. George, MD, Cem Akin, MD PhD, Karl Sotlar, MD, Olivier Hermine, MD PhD, Farrukh Awan, MD MS, Elizabeth O Hexner, MD, Michael Mauro, MD, David Sternberg, MD PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Eric Stanek, PharmD, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2014) 124 (21): 636.

https://doi.org/10.1182/blood.V124.21.636.636

Published: 2014

Journal Articles

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Jennifer A. Woyach, MD, Farrukh Awan, MD MS, Ian Flinn, Jesus G. Berdeja, MD, Elizabeth A Wiley, Sharmeen Mansoor, Ying Huang, MA, MS, Gerard Lozanski, MD, Paul A. Foster, MD, John C. Byrd, MD

Blood (2014) 124 (21): 1993.

https://doi.org/10.1182/blood.V124.21.1993.1993

Published: 2014

Journal Articles

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

Kerry A. Rogers, MD, Jennifer A. Woyach, MD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Kristie A. Blum, MD, Joseph M Flynn, DO, MPH, Samantha Jaglowski, MD MPH, Gerard Lozanski, MD, Kami J. Maddocks, MD, John C. Byrd, MD, Jeffrey A. Jones, MD

Blood (2014) 124 (21): 1997.

https://doi.org/10.1182/blood.V124.21.1997.1997

Published: 2014

Journal Articles

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Kami J. Maddocks, MD, John Pagel, MD PhD, John C. Byrd, MD, Scott Stromatt, Farrukh Awan, MD MS

Blood (2014) 124 (21): 4671.

https://doi.org/10.1182/blood.V124.21.4671.4671

Published: 2014

Journal Articles

Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients

Jiazhu Wu, B. S., Xiaojing Xu, PhD, Lirong Pei, B.S., Eun-Joon Lee, PhD, Austin Shull, B.S., Farrukh Awan, MD MS, Xiaoling Wang, PhD, Lei Fan, MD, PhD, Li Jianyong, MD PhD, Xu Wei, MD PhD, Huidong Shi, PhD

Blood (2014) 124 (21): 3552.

https://doi.org/10.1182/blood.V124.21.3552.3552

Published: 2014

Journal Articles

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Jeffrey Alan Jones, MD MPH, Susan Geyer, PhD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Joseph M Flynn, DO, MPH, Kami J. Maddocks, MD, Anissa Bingman, M.S., Amy J. Johnson, PhD, Nyla A. Heerema, PhD, Cathy Brookfield, RN, John C. Byrd, MD, Michael R. Grever, MD

Blood (2014) 124 (21): 329.

https://doi.org/10.1182/blood.V124.21.329.329

Published: 2014

Journal Articles

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Tadeusz Robak, MD, Andrzej Hellman, Javier Loscertales, MD, Ewa Lech-Maranda, MD PhD, John M. Pagel, MD PhD, Anthony R. Mato, MD, John C. Byrd, MD, Farrukh Awan, MD MS, Holger Hebart, MD, Jose A Garcia-Marco, MD PhD, Brian T. Hill, MD PhD, Michael Hallek, MD, Scott Stromatt, Janusz Kloczko, Professor

Blood (2014) 124 (21): 5642.

https://doi.org/10.1182/blood.V124.21.5642.5642

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States

Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation

Acalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: A ‘real-world’ study of efficacy and safety at a tertiary academic medical center

Policy and systems solutions to expand timely access to CAR T-cell therapy: Findings from a national survey of oncology professionals

T-cell tolerant fraction as a predictor of graft-versus-host disease in murine and human allogeneic hematopoietic cell transplantation

Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study

Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Hypertension and incident cardiovascular events following ibrutinib initiation

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only